A citation-based method for searching scientific literature

James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski, Pier F Ferrucci, Andrew Hill, John Wagstaff, Matteo S Carlino, John B Haanen, Michele Maio, Ivan Marquez-Rodas, Grant A McArthur, Paolo A Ascierto, Georgina V Long, Margaret K Callahan, Michael A Postow, Kenneth Grossmann, Mario Sznol, Brigitte Dreno, Lars Bastholt, Arvin Yang, Linda M Rollin, Christine Horak, F Stephen Hodi, Jedd D Wolchok. N Engl J Med 2015
Times Cited: 4290



Jacob Schachter, Antoni Ribas, Georgina V Long, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian Blank, Teresa M Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, Nageatte Ibrahim, Caroline Robert. Lancet 2017
Times Cited: 577




List of shared articles



Times cited

Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.
Elin Aamdal, Kari D Jacobsen, Oddbjørn Straume, Christian Kersten, Oluf Herlofsen, Jarle Karlsen, Israr Hussain, Anita Amundsen, Astrid Dalhaug, Marta Nyakas,[...]. Int J Cancer 2022
0

Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.
Christos Sachpekidis, Annette Kopp-Schneider, Leyun Pan, Dimitrios Papamichail, Uwe Haberkorn, Jessica C Hassel, Antonia Dimitrakopoulou-Strauss. Eur J Nucl Med Mol Imaging 2021
6

Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial.
Mathieu Spaas, Nora Sundahl, Eva Hulstaert, Vibeke Kruse, Sylvie Rottey, Daan De Maeseneer, Veerle Surmont, Annabel Meireson, Lieve Brochez, Dries Reynders,[...]. BMC Cancer 2021
0



Molecular Markers and Targets in Melanoma.
Cristina Teixido, Paola Castillo, Clara Martinez-Vila, Ana Arance, Llucia Alos. Cells 2021
0


First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
Jesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, John B Haanen, Christian U Blank, Maureen J B Aarts, Franchette W P J van den Berkmortel, Jan-Willem B de Groot, Geke A P Hospers, Ellen Kapiteijn,[...]. Br J Cancer 2021
0

Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma.
Chuanliang Cui, Canqiang Xu, Wenxian Yang, Zhihong Chi, Xinan Sheng, Lu Si, Yihong Xie, Jinyu Yu, Shun Wang, Rongshan Yu,[...]. NPJ Genom Med 2021
5